Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCAX NASDAQ:KALV NASDAQ:LRMR NASDAQ:PURR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCAXBicara Therapeutics$25.62+2.5%$22.02$8.48▼$26.29$1.64B-0.53578,745 shs851,723 shsKALVKalVista Pharmaceuticals$27.00$25.31$9.83▼$27.00$1.44B-0.123.07 million shsN/ALRMRLarimar Therapeutics$3.63-1.4%$3.84$2.71▼$6.42$382.29M0.831.87 million shs1.56 million shsPURRHyperliquid Strategies$7.90-2.9%$7.73$3.01▼$11.62$1.18B1.6419.31 million shs12.07 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCAXBicara Therapeutics+2.48%+11.78%+18.17%+35.41%+169.39%KALVKalVista Pharmaceuticals0.00%0.00%+0.78%+42.48%+130.77%LRMRLarimar Therapeutics-1.36%+2.54%+5.22%-25.15%+21.40%PURRHyperliquid Strategies-2.95%-19.47%+3.00%+61.89%+789,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCAXBicara Therapeutics$25.62+2.5%$22.02$8.48▼$26.29$1.64B-0.53578,745 shs851,723 shsKALVKalVista Pharmaceuticals$27.00$25.31$9.83▼$27.00$1.44B-0.123.07 million shsN/ALRMRLarimar Therapeutics$3.63-1.4%$3.84$2.71▼$6.42$382.29M0.831.87 million shs1.56 million shsPURRHyperliquid Strategies$7.90-2.9%$7.73$3.01▼$11.62$1.18B1.6419.31 million shs12.07 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCAXBicara Therapeutics+2.48%+11.78%+18.17%+35.41%+169.39%KALVKalVista Pharmaceuticals0.00%0.00%+0.78%+42.48%+130.77%LRMRLarimar Therapeutics-1.36%+2.54%+5.22%-25.15%+21.40%PURRHyperliquid Strategies-2.95%-19.47%+3.00%+61.89%+789,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCAXBicara Therapeutics 2.73Moderate Buy$30.2718.17% UpsideKALVKalVista Pharmaceuticals 2.22Hold$30.6013.33% UpsideLRMRLarimar Therapeutics 3.10Buy$13.50271.90% UpsidePURRHyperliquid Strategies 2.50Moderate Buy$9.2517.09% UpsideCurrent Analyst Ratings BreakdownLatest LRMR, PURR, KALV, and BCAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2026PURRHyperliquid Strategies Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.756/3/2026PURRHyperliquid Strategies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)5/27/2026BCAXBicara Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/27/2026LRMRLarimar Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$9.005/20/2026PURRHyperliquid Strategies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (D)5/20/2026PURRHyperliquid Strategies Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.45 ➝ $9.755/18/2026LRMRLarimar Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$13.00 ➝ $12.005/12/2026BCAXBicara Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$36.00 ➝ $37.005/12/2026BCAXBicara Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$16.00 ➝ $18.005/11/2026BCAXBicara Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$42.005/11/2026PURRHyperliquid Strategies Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$6.00 ➝ $8.00(Data available from 6/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCAXBicara TherapeuticsN/AN/AN/AN/A$7.33 per shareN/AKALVKalVista Pharmaceuticals$1.43M1,008.07N/AN/A$2.71 per share9.96LRMRLarimar TherapeuticsN/AN/AN/AN/A$0.94 per shareN/APURRHyperliquid Strategies$1M1,141.16N/AN/A$1.52 per share5.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCAXBicara Therapeutics-$137.95M-$2.78N/AN/AN/AN/A-35.89%-33.78%8/11/2026 (Estimated)KALVKalVista Pharmaceuticals-$109.52M-$3.46N/A36.00N/AN/A-341.44%-111.94%8/13/2026 (Estimated)LRMRLarimar Therapeutics-$165.67M-$2.06N/AN/AN/AN/A-134.14%-96.00%8/13/2026 (Estimated)PURRHyperliquid Strategies-$16.01M-$7.37N/AN/AN/AN/A-56.04%-52.22%N/ALatest LRMR, PURR, KALV, and BCAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026KALVKalVista Pharmaceuticals-$0.3763-$0.43-$0.0538-$0.43$39.03 million$40.86 million5/14/2026Q1 2026LRMRLarimar Therapeutics-$0.53-$0.31+$0.22-$0.31N/AN/A5/11/2026Q1 2026BCAXBicara Therapeutics-$0.72-$0.93-$0.21-$0.93N/AN/A5/7/2026Q3 2026PURRHyperliquid StrategiesN/A$1.01N/A$1.01N/A$2.63 million3/30/2026Q4 2025BCAXBicara Therapeutics-$0.72-$0.68+$0.04-$0.68N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBCAXBicara TherapeuticsN/AN/AN/AN/AN/AKALVKalVista PharmaceuticalsN/AN/AN/AN/AN/ALRMRLarimar TherapeuticsN/AN/AN/AN/AN/APURRHyperliquid StrategiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCAXBicara TherapeuticsN/A13.8513.85KALVKalVista Pharmaceuticals8.185.175.10LRMRLarimar TherapeuticsN/A4.294.29PURRHyperliquid StrategiesN/A18.2318.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCAXBicara TherapeuticsN/AKALVKalVista PharmaceuticalsN/ALRMRLarimar Therapeutics91.92%PURRHyperliquid Strategies9.45%Insider OwnershipCompanyInsider OwnershipBCAXBicara Therapeutics13.80%KALVKalVista Pharmaceuticals4.30%LRMRLarimar Therapeutics4.50%PURRHyperliquid Strategies8.48%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCAXBicara Therapeutics3265.70 million56.64 millionN/AKALVKalVista Pharmaceuticals10053.24 million50.95 millionOptionableLRMRLarimar Therapeutics30103.88 million99.21 millionOptionablePURRHyperliquid StrategiesN/A144.45 million132.20 millionN/ALRMR, PURR, KALV, and BCAX HeadlinesRecent News About These CompaniesPanther Minerals Announces Brokered Private Placement of up to $3,000,000June 16, 2026 | accessnewswire.comAHyperliquid Strategies shares jump as HYPE token strength and late-June index reconstitution fuel buyingJune 16, 2026 | quiverquant.comQHyperliquid Strategies Stock Is Surging Tuesday: What's Driving The Action?June 16, 2026 | benzinga.comWhy Is Hyperliquid Strategies Stock Gaining Monday?June 15, 2026 | benzinga.comPanther Minerals Announces Appointment of Harrison Glancy to Board of DirectorsJune 10, 2026 | accessnewswire.comAHyperliquid Strategies (PURR) Is Down 14.6% After Gamma Squeeze Speculation and Index Inclusion Buzz – What's ChangedJune 7, 2026 | finance.yahoo.comComparing HYPE & PURR: The Most Stock-Like Crypto PlayJune 5, 2026 | seekingalpha.comArthur Hayes: My $100,000 Against Yours That SOL Will Not Outperform The Hottest Coin In The MarketJune 2, 2026 | benzinga.comPURR Stock On Track For Record High After Hyperliquid Flips Dogecoin To Enter Crypto Top 10June 1, 2026 | finance.yahoo.comHyperliquid Is 'Bigger Than Nasdaq,' Says ICE CEO — HYPE Eyes New Record High, While ETFs Top $100MMay 30, 2026 | finance.yahoo.comHyperliquid Strategies (PURR) jumps as Russell Microcap inclusion chatter lifts demandMay 29, 2026 | quiverquant.comQWhy Hyperliquid Strategies Inc.’s (PURR) Stock Is Up 12.26%May 28, 2026 | aaii.comAGoldman Sachs Sells XRP and SOL ETF, Pivots to Hyperliquid in Q1 2026May 22, 2026 | memeburn.comMHyperliquid token surges toward all-time high after spot ETF inflows hit record – 'Everything is down lately except HYPE,' says analystMay 22, 2026 | msn.comThe Token Takeover: SEC Triggers Market Quake (PURR)...May 21, 2026 | marketbeat.com21Shares has a new ETF—and it's in big demand (corrected)May 20, 2026 | msn.comCathie Woods' 21Shares Has A New ETF—And It's In Big DemandMay 19, 2026 | msn.comHyperliquid Strategies (PURR) jumps as Hyperliquid’s HYPE token rally boosts its crypto-treasury narrativeMay 19, 2026 | quiverquant.comQWhy Hyperliquid Strategies Keeps Buying HYPE Despite a $165M Net LossMay 9, 2026 | memeburn.comMHyperliquid Strategies Reports $165 Million Loss as HYPE Treasury ExpandsMay 8, 2026 | financefeeds.comFHyperliquid Strategies Reports $152.5 Million Quarterly Profit as HYPE Rally Lifts TreasuryMay 8, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLRMR, PURR, KALV, and BCAX Company DescriptionsBicara Therapeutics NASDAQ:BCAX$25.62 +0.62 (+2.48%) Closing price 06/24/2026 03:59 PM EasternExtended Trading$25.64 +0.02 (+0.06%) As of 06/24/2026 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.KalVista Pharmaceuticals NASDAQ:KALV$27.00 0.00 (0.00%) As of 06/12/2026KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.Larimar Therapeutics NASDAQ:LRMR$3.63 -0.05 (-1.36%) Closing price 06/24/2026 04:00 PM EasternExtended Trading$3.68 +0.06 (+1.52%) As of 04:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.Hyperliquid Strategies NASDAQ:PURR$7.90 -0.24 (-2.95%) Closing price 06/24/2026 04:00 PM EasternExtended Trading$8.36 +0.46 (+5.82%) As of 04:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Hyperliquid Strategies Inc is a digital asset treasury company whose primary focus is to maximize shareholder value through accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain custom-built to house all of finance. Hyperliquid Strategies Inc, formerly known as Sonnet BioTherapeutics Holdings Inc., is based in NEW YORK. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why KB Home Could Reward Patient Investors Later Tesla's New NHTSA Probe Lands at the Worst Possible Time Meta's Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time ASML’s Chip Dominance Runs Into New Silicon Boundaries Frozen Assets: How Super Micro Puts AI Heat on Ice The SpaceX Sell-Off May Be More Than a Market Overreaction Why These South Korea-Focused ETFs Have More Than Doubled in 2026 Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
